Revenue: As of FY2025 Q4, the actual value is USD 30.62 M, beating the estimate of USD 28.88 M.EPS: As of FY2025 Q4, the actual value is USD 0.12, beating the estimate of USD -0.215.<h4>Fourth Quarter 2025 Financial Summary</h4>Anika Therapeutics, Inc. reported total revenue of $30.6 million for the fourth quarter of 2025, which remained flat compared to the fourth quarter of 2024. Commercial Channel revenue increased by 22% year over year to $13.3 million, while OEM Channel revenue decreased by 12% to $17.3 million. The gross margin expanded to 63%. Operating expenses were $18.5 million. GAAP income from continuing operations was $1.8 million, and adjusted net income from continuing operations was $4.6 million. Adjusted EBITDA stood at $4.5 million. As of December 31, 2025, cash and cash equivalents were $57.5 million.<h4>Full Year 2025 Financial Summary</h4>For the full year 2025, total revenue was $112.8 million, marking a 6% decrease compared to 2024. Commercial Channel revenue grew by 15% year over year to $48.4 million, while OEM Channel revenue saw a 17% decrease for the year, totaling $64.4 million. The company achieved a 57% gross margin for the year. Operating expenses were $74.9 million. GAAP loss from continuing operations was - $10.0 million, and adjusted net income from continuing operations was $1.6 million. Adjusted EBITDA for the full year was $5.3 million. Operating cash flow amounted to $11.2 million, and free cash flow was $4.4 million.<h4>Operational Metrics</h4>International OA Pain Management grew 28% in the fourth quarter and 12% for the full year 2025. Revenue from the Integrity™ Implant System more than doubled in 2025, reaching $6 million. Through the end of Q4 2025, Anika Therapeutics, Inc. funded $5.5 million of its $15 million share repurchase commitment, with $10.7 million funded to date and completion expected in Q2 2026. The company anticipates approximately $2.5 million in annualized adjusted EBITDA savings and $3.0 million in annualized stock-based compensation savings from actions initiated to reduce general and administrative expenses in the first half of 2026.<h4>Fiscal 2026 Guidance</h4>Anika Therapeutics, Inc. projects total company revenue for 2026 to be between $114 million and $122.5 million, representing a 1% to 9% year-over-year increase. Commercial Channel revenue is expected to be $53 million to $58 million, maintaining a 10% to 20% year-over-year growth. OEM Channel revenue is forecast to be $61 million to $64.5 million, remaining flat to modestly lower year over year, with Adjusted EBITDA as a percent of revenue targeted at 5% to 10%.

Anika Therap | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 30.62 M